FOLH1 and prostate cancer: Another meta-analysis [14] including 2.431 patients with intermediate- to high-risk prostate cancer, showed that 68Ga-PSMA PET/CT had greater sensitivity and specificity than mpMRI (73.7% vs. 38.9%; 97.5% vs. 82.6%) and CT (73.2% vs. 38.5%; 97.8% vs. 83.6%) for nodal staging.